Watch AVXL. Know when insiders buy.
One email the day a filing lands. Free.
AVXL
ANAVEX LIFE SCIENCES CORP.
2.85
−0.01 −0.35%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
56
WATCH · shorts 56
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $528.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$13MNET CASH $118.3M52W 2.34 – 10.26SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jun 30 | — | — | — | $6.7M | $7.8M | — | 0.08 | −$9.1M | — | — | Aug 28 |
| Q2 2026 · Mar 31 | — | — | — | −$6.5M | −$5.3M | — | -0.06 | −$4.4M | — | — | Aug 28 |
| Q1 2026 · Dec 31 | — | — | — | −$6.8M | −$5.7M | — | -0.06 | −$7.2M | — | — | Feb 9 |
| Q4 2025 · Sep 30derived | — | — | — | −$10.8M | −$9.8M | — | -0.11 | −$8.6M | — | — | Aug 28 |
| Q3 2025 · Jun 30 | — | — | — | −$14.5M | −$13.2M | — | -0.16 | −$12.5M | — | — | Aug 28 |
| Q2 2025 · Mar 31 | — | — | — | −$12.5M | −$11.2M | — | -0.13 | −$5.9M | — | — | Aug 28 |
| Q1 2025 · Dec 31 | — | — | — | −$13.6M | −$12.1M | — | -0.14 | −$12.1M | — | — | Feb 9 |
| Q4 2024 · Sep 30derived | — | — | — | −$14.3M | −$11.6M | — | -0.14 | −$6.7M | — | — | Aug 28 |
| Q3 2024 · Jun 30 | — | — | — | −$14.6M | −$12.2M | — | -0.14 | −$5.2M | — | — | Aug 12 |
| Q2 2024 · Mar 31 | — | — | — | −$12.6M | −$10.5M | — | -0.13 | −$11.7M | — | — | May 13 |
| Q1 2024 · Dec 31 | — | — | — | −$11.4M | −$8.6M | — | -0.11 | −$7.3M | — | — | Feb 12 |
| Q4 2023 · Sep 30derived | — | — | — | −$12.7M | −$10.1M | — | -0.13 | −$5.8M | — | — | Aug 28 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Sep 30 | — | — | −$51.4M | −$46.4M | — | -0.54 | −$39M | — | — | — | — |
| FY2024 · to Sep 30 | — | — | −$52.9M | −$43M | — | -0.52 | −$30.8M | — | — | — | — |
| FY2023 · to Sep 30 | — | — | −$55.8M | −$47.5M | — | -0.60 | −$27.8M | — | — | — | — |
| FY2022 · to Sep 30 | — | — | −$51M | −$48M | — | -0.62 | −$24.2M | — | — | — | — |
| FY2021 · to Sep 30 | — | — | −$42M | −$37.9M | — | -0.54 | −$30.4M | — | — | — | — |
| FY2020 · to Sep 30 | — | — | −$31.1M | −$26.3M | — | -0.45 | −$21.3M | — | — | — | — |
Every number comes from ANAVEX LIFE SCIENCES CORP.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.